Hepatitis C infection in hemodialysis patients: A review

World Journal of Hepatology

Volumn 7, Issue 6, 2015, Pages 885-895

  Etik, Digdem Ozer ^a   Ocal, Serkan ^a   Boyacioglu, Ahmet Sedat ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

End stage renal disease; Hemodialysis; Hepatitis C treatment; Hepatitis C virus; Kidney transplantation

Indexed keywords

EID: 84928943901     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i6.885     Document Type: Article

References (94)

1. Selcuk H, Kanbay M, Korkmaz M, Gur G, Akcay A, Arslan H, Ozdemir N, Yilmaz U, Boyacioglu S. Distribution of HCV genotypes in patients with end-stage renal disease according to type of dialysis treatment. Dig Dis Sci 2006; 51: 1420-1425 [PMID: 16868830 DOI: 10.1007/s10620-005-9025-9]
2. Mangia A, Burra P, Ciancio A, Fagiuoli S, Guido M, Picciotto A, Fabrizi F. Hepatitis C infection in patients with chronic kidney disease. Int J Artif Organs 2008; 31: 15-33 [PMID: 18286451]
3. Perico N, Cattaneo D, Bikbov B, Remuzzi G. Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol 2009; 4: 207-220 [PMID: 19129320 DOI: 10.2215/CJN.03710708]
4. Aoufi Rabih S, García Agudo R. Management of HCV infection in chronic kidney disease. Nefrologia 2011; 31: 260-267 [PMID: 21407274 DOI: 10.3265/Nefrologia.pre2011.Jan.10768]
5. Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, Saito A, Rayner HC, Kurokawa K, Port FK, Held PJ, Young EW. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003; 14: 3270-3277 [PMID: 14638926 DOI: 10.1097/01.ASN.0000100127.54107.57]
6. Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, Rayner HC, Greenwood RN, Akiba T, Young EW. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004; 65: 2335-2342 [PMID: 15149347 DOI: 10.1111/j.1523-1755.2004.00649. x]
7. Di Napoli A, Pezzotti P, Di Lallo D, Petrosillo N, Trivelloni C, Di Giulio S. Epidemiology of hepatitis C virus among longterm dialysis patients: a 9-year study in an Italian region. Am J Kidney Dis 2006; 48: 629-637 [PMID: 16997059 DOI: 10.1053/j.ajkd.2006.07.004]
8. Sun J, Yu R, Zhu B, Wu J, Larsen S, Zhao W. Hepatitis C infection and related factors in hemodialysis patients in china: systematic review and meta-analysis. Ren Fail 2009; 31: 610-620 [PMID: 19839861 DOI: 10.1080/08860220903003446]
9. Alavian SM, Kabir A, Ahmadi AB, Lankarani KB, Shahbabaie MA, Ahmadzad-Asl M. Hepatitis C infection in hemodialysis patients in Iran: a systematic review. Hemodial Int 2010; 14: 253-262 [PMID: 20491973 DOI: 10.1111/j.1542-4758.2010.00437. x]
10. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2002; 18: 52-61 [PMID: 15663766 DOI: 10.1111/j.1525-139X.2005.18108.x]
11. Patel PR, Thompson ND, Kallen AJ, Arduino MJ. Epidemiology, surveillance, and prevention of hepatitis C virus infections in hemodialysis patients. Am J Kidney Dis 2010; 56: 371-378 [PMID: 20570422 DOI: 10.1053/j.ajkd.2010.01.025]
12. Zampieron A, Jayasekera H, Elseviers M, Lindley E, DeVos JY, Visser R, Harrington M. European study on epidemiology and management of hepatitis C virus (HCV) infection in the haemodialysis population. Part 3: prevalence and incidence. EDTNA ERCA J 2006; 32: 42-44 [PMID: 16700168 DOI: 10.1111/j.1755-6686.2006.tb00445.x]
13. Süleymanlar G, Alti{dotless}parmak MR, Seyahi N, Trabulus S. National hemodialysis, transplantation and nephrology registry report of Turkey. I˙stanbul: Turkish Society of Nephrology, 2012
14. Gordon CE, Balk EM, Becker BN, Crooks PA, Jaber BL, Johnson CA, Michael MA, Pereira BJ, Uhlig K, Levin A. KDOQI US commentary on the KDIGO clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in CKD. Am J Kidney Dis 2008; 52: 811-825 [PMID: 18971009 DOI: 10.1053/j.ajkd.2008.08.005]
15. Espinosa M, Martn-Malo A, Ojeda R, Santamara R, Soriano S, Aguera M, Aljama P. Marked reduction in the prevalence of hepatitis C virus infection in hemodialysis patients: causes and consequences. Am J Kidney Dis 2004; 43: 685-689 [PMID: 15042545 DOI: 10.1053/j.ajkd.2003.12.030]
16. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Miller LG, Daar ES, Gjertson DW, Kopple JD, Greenland S. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol 2007; 18: 1584-1593 [PMID: 17429053 DOI: 10.1681/ASN.2006070736]
17. Lee JJ, Lin MY, Chang JS, Hung CC, Chang JM, Chen HC, Yu ML, Hwang SJ. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS One 2014; 9: e100790 [PMID: 24971499 DOI: 10.1371/journal.pone.0100790]
18. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Metaanalysis: Effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther 2004; 20: 1271-1277 [PMID: 15606388 DOI: 10.1111/j.1365-2036.2004.02290.x]
19. Sezer S, Ozdemir FN, Akcay A, Arat Z, Boyacioglu S, Haberal M. Renal transplantation offers a better survival in HCV-infected ESRD patients. Clin Transplant 2004; 18: 619-623 [PMID: 15344970 DOI: 10.1111/j.1399-0012.2004.00252.x]
20. Ruhi{dotless} Ç, Süleymanlar I˙, Koçak H, Yilmaz VT, Çolak D, Di{dotless}nçkan A, Gürkan A, Ersoy F, Yakupoğlu G, Süleymanlar G. The impact of hepatitis C virus infection on long-term outcome in renal transplant patients. Turk J Gastroenterol 2011; 22: 165-170 [PMID: 21796553]
21. Roth D, Gaynor JJ, Reddy KR, Ciancio G, Sageshima J, Kupin W, Guerra G, Chen L, Burke GW. Effect of kidney transplantation on outcomes among patients with hepatitis C. J Am Soc Nephrol 2011; 22: 1152-1160 [PMID: 21546575 DOI: 10.1681/ASN.2010060668]
22. Ingsathit A, Kamanamool N, Thakkinstian A, Sumethkul V. Survival advantage of kidney transplantation over dialysis in patients with hepatitis C: a systematic review and meta-analysis. Transplantation 2013; 95: 943-948 [PMID: 23425817 DOI: 10.1097/TP.0b013e3182848de2]
23. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001; 50: 1-43 [PMID: 11349873]
24. Bianco A, Bova F, Nobile CG, Pileggi C, Pavia M. Healthcare workers and prevention of hepatitis C virus transmission: exploring knowledge, attitudes and evidence-based practices in hemodialysis units in Italy. BMC Infect Dis 2013; 13: 76 [PMID: 23391009 DOI: 10.1186/1471-2334-13-76]
25. Tang S, Lai KN. Chronic viral hepatitis in hemodialysis patients. Hemodial Int 2005; 9: 169-179 [PMID: 16191066 DOI: 10.1111/j.1492-7535.2005.01129.x]
26. Lopes EP, Gouveia EC, Albuquerque AC, Sette LH, Mello LA, Moreira RC, Coelho MR. Determination of the cut-off value of serum alanine aminotransferase in patients undergoing hemodialysis, to identify biochemical activity in patients with hepatitis C viremia. J Clin Virol 2006; 35: 298-302 [PMID: 16290052 DOI: 10.1016/j.jcv.2005.09.010]
27. Liu CH, Kao JH. Treatment of hepatitis C virus infection in patients with end-stage renal disease. J Gastroenterol Hepatol 2011; 26: 228-239 [PMID: 21261711 DOI: 10.1111/j.1440-1746.2010.06488.x]
28. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264 [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023]
29. Kaiser T, Damerow HC, Tenckhoff S, Finger A, Böttcher I, Hafer C, Schwarz A, Lüth JB, Schmidt Gürtler H, Colucci G, Manns MP, Wedemeyer H, Tillmann HL. Kinetics of hepatitis C viral RNA and HCV-antigen during dialysis sessions: evidence for differential viral load reduction on dialysis. J Med Virol 2008; 80: 1195-1201 [PMID: 18461613 DOI: 10.1002/jmv.21190]
30. Perez RM, Ferraz ML, Figueiredo MS, Contado D, Koide S, Ferreira AP, Cendoroglo Neto M, Medina Pestana JO, Silva AE. Unexpected distribution of hepatitis C virus genotypes in patients on hemodialysis and kidney transplant recipients. J Med Virol 2003; 69: 489-494 [PMID: 12601756 DOI: 10.1002/jmv.10336]
31. Martin P, Carter D, Fabrizi F, Dixit V, Conrad AJ, Artinian L, Peacock V, Han S, Wilkinson A, Lassman CR, Danovitch G. Histopathological features of hepatitis C in renal transplant candidates [see comment]. Transplantation 2000; 69: 1479-1484 [PMID: 10798774 DOI: 10.1097/00007890-200004150-00045]
32. Boyacioğlu S, Gür G, Yilmaz U, Korkmaz M, Demirhan B, Bilezikçi B, Ozdemir N. Investigation of possible clinical and laboratory predictors of liver fibrosis in hemodialysis patients infected with hepatitis C virus. Transplant Proc 2004; 36: 50-52 [PMID: 15013298 DOI: 10.1016/j.transproceed.2003.11.066]
33. Canbakan M, Senturk H, Canbakan B, Toptas T, Tabak O, Ozaras R, Tabak F, Balci{dotless} H, Sut N, Ozbay G. Validation of biochemical markers for the prediction of liver fibrosis and necroinflammatory activity in hemodialysis patients with chronic hepatitis C. Nephron Clin Pract 2011; 117: c289-c295 [PMID: 20847572 DOI: 10.1159/000320751]
34. Gürsoy M, Bilezikci B, Colak T, Köksal R, Demirhan B, Karavelioğlu D, Boyacioğlu S, Bilgin N, Arslan G. Histologic outcome of hepatitis C virus infection in renal transplant recipients and the effect of pretransplantation interferon treatment. Transplant Proc 2000; 32: 558-560 [PMID: 10812112 DOI: 10.1016/S0041-1345(00)00889-7]
35. Tang IY, Walzer N, Aggarwal N, Tzvetanov I, Cotler S, Benedetti E. Management of the kidney transplant patient with chronic hepatitis C infection. Int J Nephrol 2011; 2011: 245823 [PMID: 21603155 DOI: 10.4061/2011/245823]
36. Ahmad A, Hasan F, Abdeen S, Sheikh M, Kodaj J, Nampoory MR, Johny KV, Asker H, Siddique I, Thalib L, Al-Nakib B. Transjugular liver biopsy in patients with end-stage renal disease. J Vasc Interv Radiol 2004; 15: 257-260 [PMID: 15028810]
37. Liu CH, Liang CC, Huang KW, Liu CJ, Chen SI, Lin JW, Hung PH, Tsai HB, Lai MY, Chen PJ, Chen JH, Chen DS, Kao JH. Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients. Clin J Am Soc Nephrol 2011; 6: 1057-1065 [PMID: 21393486 DOI: 10.2215/CJN.04320510]
38. Liu CH, Liang CC, Liu CJ, Hsu SJ, Lin JW, Chen SI, Hung PH, Tsai HB, Lai MY, Chen PJ, Chen JH, Chen DS, Kao JH. The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C. Kidney Int 2010; 78: 103-109 [PMID: 20357753 DOI: 10.1038/ki.2010.74]
39. Kellner P, Anadol E, Hüneburg R, Hundt F, Bös D, Klein B, Woitas RP, Spengler U, Sauerbruch T, Trebicka J. The effect of hemodialysis on liver stiffness measurement: a single-center series. Eur J Gastroenterol Hepatol 2013; 25: 368-372 [PMID: 23114792 DOI: 10.1097/MEG.0b013e32835ad180]
40. Botero RC. Should patients with chronic hepatitis C infection be transplanted? Transplant Proc 2004; 36: 1449-1454 [PMID: 15251356 DOI: 10.1016/j.transproceed.2004.06.003]
41. Morales JM, Bloom R, Roth D. Kidney transplantation in the patient with hepatitis C virus infection. Contrib Nephrol 2012; 176: 77-86 [PMID: 22310783 DOI: 10.1159/000332385]
42. Carbone M, Cockwell P, Neuberger J. Hepatitis C and kidney transplantation. Int J Nephrol 2011; 2011: 593291 [PMID: 21755059 DOI: 10.4061/2011/593291]
43. Eason JD, Gonwa TA, Davis CL, Sung RS, Gerber D, Bloom RD. Proceedings of Consensus Conference on Simultaneous Liver Kidney Transplantation (SLK). Am J Transplant 2008; 8: 2243-2251 [PMID: 18808402 DOI: 10.1111/j.1600-6143.2008.02416.x]
44. Roth D, Bloom R. Selection and management of hepatitis C virus-infected patients for the kidney transplant waiting list. Contrib Nephrol 2012; 176: 66-76 [PMID: 22310782 DOI: 10.1159/000333774]
45. Kim E, Ko HH, Yoshida EM. Treatment issues surrounding hepatitis C in renal transplantation: a review. Ann Hepatol 2011; 10: 5-14 [PMID: 21301003]
46. Terrault NA, Adey DB. The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment. Clin J Am Soc Nephrol 2007; 2: 563-575 [PMID: 17699464 DOI: 10.2215/CJN.02930806]
47. Kamar N, Rostaing L, Selves J, Sandres-Saune K, Alric L, Durand D, Izopet J. Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant 2005; 5: 1704-1712 [PMID: 15943629 DOI: 10.1111/j.1600-6143.2005.00918.x]
48. Morales JM, Aguado JM. Hepatitis C and renal transplantation. Curr Opin Organ Transplant 2012; 17: 609-615 [PMID: 23111646 DOI: 10.1097/MOT.0b013e32835a2bac]
49. Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997; 51: 981-999 [PMID: 9083262 DOI: 10.1038/ki.1997.139]
50. Izopet J, Rostaing L, Sandres K, Cisterne JM, Pasquier C, Rumeau JL, Duffaut M, Durand D, Puel J. Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. J Infect Dis 2000; 181: 852-858 [PMID: 10720504 DOI: 10.1086/315355]
51. Du LY, Tang H. Treatment of HCV patients before and after renal transplantation. Hepat Mon 2011; 11: 880-886 [PMID: 22308151 DOI: 10.5812/kowsar.1735143X.712]
52. Fabrizi F, Lunghi G, Dixit V, Martin P. Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients. Aliment Pharmacol Ther 2006; 24: 1413-1422 [PMID: 17081162 DOI: 10.1111/j.1365-2036.2006.03151.x]
53. Kamar N, Sandres-Saune K, Selves J, Ribes D, Cointault O, Durand D, Izopet J, Rostaing L. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am J Kidney Dis 2003; 42: 184-192 [PMID: 12830471 DOI: 10.1016/S0272-6386(03)00422-0]
54. Sharma RK, Bansal SB, Gupta A, Gulati S, Kumar A, Prasad N. Chronic hepatitis C virus infection in renal transplant: treatment and outcome. Clin Transplant 2006; 20: 677-683 [PMID: 17100715 DOI: 10.1111/j.1399-0012.2006.00534.x]
55. Manuel O, Baid-Agrawal S, Moradpour D, Pascual M. Immunosuppression in hepatitis C virus-infected patients after kidney transplantation. Contrib Nephrol 2012; 176: 97-107 [PMID: 22310785 DOI: 10.1159/000332387]
56. Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, Holt C, Lewin KJ, Busuttil RW, Martin P. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997; 92: 1453-1457 [PMID: 9317061]
57. Luan FL, Schaubel DE, Zhang H, Jia X, Pelletier SJ, Port FK, Magee JC, Sung RS. Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C. Transplantation 2008; 85: 1601-1606 [PMID: 18551066 DOI: 10.1097/TP.0b013e3181722f3a]
58. Akalin E, Murphy B, Sehgal V, Ames S, Daly L, Bromberg JS. Rapid steroid withdrawal in hepatitis C virus-positive kidney transplant recipients. Clin Transplant 2004; 18: 384-389 [PMID: 15233814 DOI: 10.1111/j.1399-0012.2004.00177.x]
59. Hsu SH, Yeh ML, Wang SN. New insights in recurrent HCV infection after liver transplantation. Clin Dev Immunol 2013; 2013: 890517 [PMID: 23710205 DOI: 10.1155/2013/890517]
60. Nakagawa M, Sakamoto N, Tanabe Y, Koyama T, Itsui Y, Takeda Y, Chen CH, Kakinuma S, Oooka S, Maekawa S, Enomoto N, Watanabe M. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology 2005; 129: 1031-1041 [PMID: 16143140 DOI: 10.1053/j.gastro.2005.06.031]
61. Kahraman A, Witzke O, Scherag A, Pütter C, Miller M, Dechêne A, Ross SR, Gerken G, Hilgard P. Impact of immunosuppressive therapy on hepatitis C infection after renal transplantation. Clin Nephrol 2011; 75: 16-25 [PMID: 21176747]
62. Pan Q, de Ruiter PE, Metselaar HJ, Kwekkeboom J, de Jonge J, Tilanus HW, Janssen HL, van der Laan LJ. Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo. Hepatology 2012; 55: 1673-1683 [PMID: 22213147 DOI: 10.1002/hep.25562]
63. López-Medrano F, Fernández-Ruiz M, Morales JM, San-Juan R, Cervera C, Carratalá J, Torre-Cisneros J, Gavaldá J, Muñoz P, Len O, Martín-Dávila P, Ramos A, Montejo M, Lumbreras C, Moreno A, Aguado JM. Impact of hepatitis C virus infection on the risk of infectious complications after kidney transplantation: data from the RESITRA/REIPI cohort. Transplantation 2011; 92: 543-549 [PMID: 21869745 DOI: 10.1097/TP.0b013e318225dbae]
64. Torres J, Aguado JM, San Juan R, Andrés A, Sierra P, López-Medrano F, Morales JM. Hepatitis C virus, an important risk factor for tuberculosis in immunocompromised: experience with kidney transplantation. Transpl Int 2008; 21: 873-878 [PMID: 18482173 DOI: 10.1111/j.1432-2277.2008.00694.x]
65. Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003; 42: 631-657 [PMID: 14520615 DOI: 10.1016/S0272-6386(03)00828-X]
66. Sandri AM, Elewa U, Poterucha JJ, Fervenza FC. Treatment of hepatitis C-mediated glomerular disease. Nephron Clin Pract 2011; 119: c121-129; discussion c129-130 [PMID: 21757949 DOI: 10.1159/000325220]
67. Kamar N, Rostaing L, Boulestin A, Sandres K, Dubois M, Ribes D, Modesto A, Durand D, Izopet J. Evolution of hepatitis C virus quasispecies in renal transplant patients with de novo glomerulonephritis. J Med Virol 2003; 69: 482-488 [PMID: 12601755 DOI: 10.1002/jmv.10335]
68. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Kanwal F, Dulai G. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant 2005; 5: 2433-2440 [PMID: 16162192 DOI: 10.1111/j.1600-6143.2005.01040.x]
69. Bloom RD, Lake JR. Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients. Am J Transplant 2006; 6: 2232-2237 [PMID: 16869798 DOI: 10.1111/j.1600-6143.2006.01457.x]
70. Bloom RD, Rao V, Weng F, Grossman RA, Cohen D, Mange KC. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 2002; 13: 1374-1380 [PMID: 11961026 DOI: 10.1097/01.ASN.0000012382.97168.E0]
71. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178-185 [PMID: 12603213 DOI: 10.1034/j.1600-6143.2003.00010.x]
72. Zignego AL, Giannini C, Gragnani L. HCV and lymphoproliferation. Clin Dev Immunol 2012; 2012: 980942 [PMID: 22852020 DOI: 10.1155/2012/980942]
73. Burra P, Buda A, Livi U, Rigotti P, Zanus G, Calabrese F, Caforio A, Menin C, Canova D, Farinati F, Luciana Aversa SM. Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection? Eur J Gastroenterol Hepatol 2006; 18: 1065-1070 [PMID: 16957512 DOI: 10.1097/01.meg.0000231752.50587.ae]
74. Esforzado N, Campistol JM. Treatment of hepatitis C in dialysis patients. Contrib Nephrol 2012; 176: 54-65 [PMID: 22310781 DOI: 10.1159/000332383]
75. Rostaing L, Weclawiak H, Izopet J, Kamar N. Treatment of hepatitis C virus infection after kidney transplantation. Contrib Nephrol 2012; 176: 87-96 [PMID: 22310784 DOI: 10.1159/000333775]
76. Goodkin DA, Bieber B, Gillespie B, Robinson BM, Jadoul M. Hepatitis C infection is very rarely treated among hemodialysis patients. Am J Nephrol 2013; 38: 405-412 [PMID: 24192505 DOI: 10.1159/000355615]
77. Weclawiak H, Kamar N, Ould-Mohamed A, Cardeau-Desangles I, Izopet J, Rostaing L. Treatment of chronic hepatitis C virus infection in dialysis patients: an update. Hepat Res Treat 2010; 2010: 267412 [PMID: 21152180 DOI: 10.1155/2010/267412]
78. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374 [PMID: 19330875 DOI: 10.1002/hep.22759]
79. Fabrizi F, Ganeshan SV, Lunghi G, Messa P, Martin P. Antiviral therapy of hepatitis C in chronic kidney diseases: meta-analysis of controlled clinical trials. J Viral Hepat 2008; 15: 600-606 [PMID: 18444984 DOI: 10.1111/j.1365-2893.2008.00990.x]
80. Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and metaanalysis of treatment efficacy and harms. Am J Kidney Dis 2008; 51: 263-277 [PMID: 18215704 DOI: 10.1053/j.ajkd.2007.11.003]
81. Alavian SM, Tabatabaei SV. Meta-analysis of factors associated with sustained viral response in patients on hemodialysis treated with standard or pegylated interferon for hepatitis C infection. Iran J Kidney Dis 2010; 4: 181-194 [PMID: 20622305]
82. Okoh EJ, Bucci JR, Simon JF, Harrison SA. HCV in patients with end-stage renal disease. Am J Gastroenterol 2008; 103: 2123-2134 [PMID: 18796105 DOI: 10.1111/j.1572-0241.2008.01981.x]
83. Carrion AF, Fabrizi F, Martin P. Should ribavirin be used to treat hepatitis C in dialysis patients? Semin Dial 2011; 24: 272-274 [PMID: 21480995 DOI: 10.1111/j.1525-139X.2011.00851.x]
84. Liu CH, Huang CF, Liu CJ, Dai CY, Liang CC, Huang JF, Hung PH, Tsai HB, Tsai MK, Chen SI, Lin JW, Yang SS, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Yu ML, Kao JH. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med 2013; 159: 729-738 [PMID: 24297189 DOI: 10.7326/0003-4819-159-11-201312030-00005]
85. Tan AC, Brouwer JT, Glue P, van Leusen R, Kauffmann RH, Schalm SW, de Vries RA, Vroom B. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant 2001; 16:193-195 [PMID: 11209032]
86. Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc 2004; 36: 1831-1834 [PMID: 15350490]
87. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006; 13: 316-321 [PMID: 16637862]
88. Rendina M, Schena A, Castellaneta NM, Losito F, Amoruso AC, Stallone G, Schena FP, Di Leo A, Francavilla A. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 2007; 46: 768-774 [PMID: 17383045 DOI: 10.1016/j.jhep.2006.12.016]
89. Lee LY, Tong CY, Wong T, Wilkinson M. New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials. Int J Clin Pract 2012; 66: 342-355 [PMID: 22420497 DOI: 10.1111/j.1742-1241.2012.02895.x]
90. Kawaoka T, Aikata H, Miyaki D, Murakami E, Azakami T, Takaki S, Nagaoki Y, Hashimoto Y, Katamura Y, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Tashiro H, Ohdan H, Chayama K. Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferonsensitivity determining region. Hepatol Res 2011; 41: 1126-1131 [PMID: 22032680 DOI: 10.1111/j.1872-034X.2011.00853.x]
91. Pawlotsky JM. New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development. Semin Liver Dis 2014; 34: 22-29 [PMID: 24782255 DOI: 10.1055/s-0034-1371007]
92. Fabrizi F, Penatti A, Messa P, Martin P. Treatment of hepatitis C after kidney transplant: a pooled analysis of observational studies. J Med Virol 2014; 86: 933-940 [PMID: 24610278 DOI: 10.1002/jmv.23919]
93. Zimner-Rapuch S, Janus N, Deray G, Launay-Vacher V. New therapies for hepatitis C: considerations in patients with renal impairment. Drugs 2014; 74: 1307-1313 [PMID: 25060981 DOI: 10.1007/s40265-014-0268-7]
94. Degasperi E, Aghemo A. Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives. Hepat Med 2014; 6: 25-33 [PMID: 24822024 DOI: 10.2147/HMER. S44375]